Bracco Diagnostics recently reported that the U.S. Food and Drug Administration has approved its new ultrasound contrast agent Lumason for injectable suspension, indicated for use in adults with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.
Marie Paule Kieny, told reporters that the clinical trials will be conducted on the two "most advanced" vaccines and "at least 5 more vaccines" will be in the clinic in the first months of 2015. Kieny said the pharmaceutical companies developing these vaccines "are committing to ramping up the production capacity to millions of doses to be availabl
Ebola vaccine trials are to start in west Africa in December, a month earlier than planned, and hundreds of thousands of doses will be available by mid-2015, the World Health Organisation says. The first vaccinations of health workers and others at high risk, including burial teams, are likely to take place in Liberia, with Sierra Leone not far beh
Gilead Sciences recently reported that the U.S. Food and Drug Administration has approved Harvoni, a once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Gilead Sciences reported in a release that Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor...
Valby, Copenhagen, 2014-10-25 11:30 CEST In the per-protocol population desmoteplase was associated with better functional outcome compared to placebo as assessed by the modified Rankin Scale In additional data analyses it is suggested that magnetic resonance imaging is more sensitive than computed tomography scanning for identifying appropri
Pfizer presented data from a Phase 1/ Phase 2 study evaluating the safety, tolerability and immunogenicity of a single-dose vaccine of Pfizer's investigational 4- antigen Staphylococcus aureus candidate vaccine in healthy adults. Kathrin Jansen, senior vice president of the Vaccine Research and Early Development unit for Pfizer. IDWeek 2014 is an a
By a News Reporter-Staff News Editor at Investment Weekly News Rigrodsky& Long, P.A.: Do you, or did you, own shares of Pacira Pharmaceuticals, Inc.? Rigrodsky& Long, P.A., including former Special Assistant United States Attorney, Timothy J. MacFall, announces that a complaint has been filed in the United States District Court for the District o
The outbreak of the deadly Ebola virus in West Africa that has killed thousands of people so far has only become an issue of concern since reports of individuals from the West being infected with the disease have surfaced. Stephen Hall, a CEO of a pharmaceutical company explains why: "Traditional investors have not been enthusiastic about funding t
By a News Reporter-Staff News Editor at Drug Week A patent application by the inventors Gibson, Susan P.; Vanhove, Geertrui F., filed on March 27, 2014, was made available online on October 9, 2014, according to news reporting originating from Washington, D.C., by NewsRx correspondents. This patent application is assigned to Jazz Pharmaceuticals,
AbbVie's HUMIRA adalimumab Receives U.S. By a News Reporter-Staff News Editor at Health& Medicine Week AbbVie announced that the U.S. Food and Drug Administration has approved the extension of the HUMIRA indication for moderately to severely active polyarticular juvenile idiopathic arthritis to reducing signs and symptoms in patients ages 2 an
In the U.S., the FDA has accepted for priority review the Biologics License Application for previously treated advanced melanoma and the Prescription Drug User Fee Act goal date for a decision is March 30, 2015. The FDA also granted Opdivo Breakthrough Therapy Designation for this indication. During the third quarter of 2014, the Company and Pfizer
ReportsnReports.com adds Research and Development Trend Forecast of Chinese Patent Medicine in China, 2014-2018 market report to the pharmaceuticals category of its online industry research reports library. It analyses the policy environment, market scale, competition pattern, development trend and key enterprises in Chinese patent medicine...
THIRD QUARTER 2014 (JUL SEP) ? Net sales in the quarter amounted to SEK 22.4 (16.8) million, corresponding to an increase of 34 percent. ? Net sales for consumables in the quarter amounted to SEK 21.0 (16.8) million, corresponding to an increase of 25 percent in SEK. Sales for consumables increased by 18 percent in local currency. ? Ope
By a News Reporter-Staff News Editor at Health& Medicine Week Covidien plc announced U.S. Food and Drug Administration 510 clearance for the Nellcor? Portable SpO2 Patient Monitoring System. Part of a comprehensive Covidien respiratory function monitoring portfolio, this convenient, handheld patient monitor is simple to use and ideal for fast,
ALEXANDRIA, Va., Oct. 24 Cydex Pharmaceuticals, Lenexa, Kansas, has been assigned a patent developed by six co-inventors for "formulations containing clopidogrel and sulfoalkyl ether cyclodextrin and methods of use." The co-inventors are Karen T. Johnson, Lawrence, Kansas, Rebecca L. Wedel, Lawrence, Kansas, Stephen G. Machatha, Overland Park, Ka
DARA BioSciences, Inc., an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced it is supporting Breastcancer.org with its Sponsor level...
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing a pipeline of abuse-deterrent opioids and niche generic products, today announced key management appointments of Dr. Dr. Smith previously held the positions of Chief Intellectual Property Counsel for Alpharma, Inc. and before that Head of North American Intellectual Proper
The U.S. Department of Health and Human Services' Food and Drug Administration issued the following news release:. The U.S. Food and Drug Administration yesterday approved Obizur for the treatment of bleeding episodes in adults with acquired hemophilia A. "The approval of this product provides an important therapeutic option for use in the care of
Oct. 24 BRANFORD Connecticut's reputation as a center for biomedical research received a boost Thursday with an announcement that the Icahn School of Medicine at Mount Sinai has opened a state-of-the-art genomics research facility on Commercial Street. "We are investing in industry leaders like the Icahn School of Medicine at Mount Sinai so th
Imprimis Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary sterile and topical compounded drug formulations, today reported on clinical findings demonstrating the safety and benefits of Dropless cataract surgery and provided an update resulting from the recent American...
Release date- 22102014- New Brunswick, N.J- Johnson& Johnson today announced that it has made a commitment of up to $200 million to accelerate and significantly expand the production of an Ebola vaccine program in development at its Janssen Pharmaceutical Companies. The vaccine regimen, which was discovered in a collaborative research program with
Release date- 23102014- ROSWELL, Ga- Kimberly-Clark Health Care, soon to be Halyard Health, announced today that it is the first and only manufacturer to receive 510 clearance from the U.S. Food and Drug Administration for use of their sterilization wrap portfolio with all standard sterilization modalities. 'Providing innovation in sterilization te
Lundbeck LLC announced today that it has received a Complete Response Letter from the U.S. Food and Drug Administration for its New Drug Application seeking approval of Carbella? injection, an investigational intravenous formulation of the anti-epileptic drug carbamazepine. Lundbeck is currently addressing requests specified in the letter, and is
Minnesota native Don Wright, who has completed 84 marathons in the last 11 years all of them with multiple myeloma will be a featured participant in the inaugural event of a new partnership fighting to accelerate access to new medications for cancer patients. The Minneapolis event is a partnership created by the Richard Schulze Foundation, es
Tumor BRACAnalysis CDx Will Identify More Patients for Treatment With PARP Inhibitors SALT LAKE CITY and ZURICH, Oct. 24, 2014 Myriad Genetics, Inc. today announced it has established a Tumor BRACAnalysis CDx laboratory in Europe. Earlier today, the European Medicines Agency's Committee for Medicinal Products for Human Use recommended marketing..